Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Update

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 15,500 shares, a decline of 7.2% from the July 15th total of 16,700 shares. Based on an average daily trading volume, of 7,400 shares, the short-interest ratio is currently 2.1 days. Currently, 0.2% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals in a report on Wednesday, August 14th. They issued a “hold” rating for the company.

Cumberland Pharmaceuticals Price Performance

Shares of CPIX stock opened at $1.36 on Tuesday. Cumberland Pharmaceuticals has a 12-month low of $1.34 and a 12-month high of $2.36. The firm has a market capitalization of $19.30 million, a price-to-earnings ratio of -2.31 and a beta of 0.23. The company has a quick ratio of 1.21, a current ratio of 1.37 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average of $1.47 and a 200-day moving average of $1.66.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.